These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1225 related articles for article (PubMed ID: 29242642)

  • 1. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological reactivation of p53 as a strategy to treat cancer.
    Zawacka-Pankau J; Selivanova G
    J Intern Med; 2015 Feb; 277(2):248-259. PubMed ID: 25495071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.
    Zhang S; Carlsen L; Hernandez Borrero L; Seyhan AA; Tian X; El-Deiry WS
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454137
    [No Abstract]   [Full Text] [Related]  

  • 5. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.
    Blanden AR; Yu X; Loh SN; Levine AJ; Carpizo DR
    Drug Discov Today; 2015 Nov; 20(11):1391-7. PubMed ID: 26205328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational approaches targeting the p53 pathway for anti-cancer therapy.
    Essmann F; Schulze-Osthoff K
    Br J Pharmacol; 2012 Jan; 165(2):328-44. PubMed ID: 21718309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
    Garufi A; Pistritto G; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Awakening the "guardian of genome": reactivation of mutant p53.
    Binayke A; Mishra S; Suman P; Das S; Chander H
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological reactivation of p53 in the era of precision anticancer medicine.
    Tuval A; Strandgren C; Heldin A; Palomar-Siles M; Wiman KG
    Nat Rev Clin Oncol; 2024 Feb; 21(2):106-120. PubMed ID: 38102383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.
    McCubrey JA; Lertpiriyapong K; Fitzgerald TL; Martelli AM; Cocco L; Rakus D; Gizak A; Libra M; Cervello M; Montalto G; Yang LV; Abrams SL; Steelman LS
    Adv Biol Regul; 2017 Jan; 63():32-48. PubMed ID: 27776972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.
    Zhu J; Sammons MA; Donahue G; Dou Z; Vedadi M; Getlik M; Barsyte-Lovejoy D; Al-awar R; Katona BW; Shilatifard A; Huang J; Hua X; Arrowsmith CH; Berger SL
    Nature; 2015 Sep; 525(7568):206-11. PubMed ID: 26331536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations in cancer.
    Muller PA; Vousden KH
    Nat Cell Biol; 2013 Jan; 15(1):2-8. PubMed ID: 23263379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological activation of p53 in cancer cells.
    Athar M; Elmets CA; Kopelovich L
    Curr Pharm Des; 2011; 17(6):631-9. PubMed ID: 21391904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should mutant TP53 be targeted for cancer therapy?
    Wang Z; Strasser A; Kelly GL
    Cell Death Differ; 2022 May; 29(5):911-920. PubMed ID: 35332311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of
    Strandgren C; Wiman KG
    Ups J Med Sci; 2024; 129():. PubMed ID: 38863730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.